Catalyst Watch: Tesla, Boeing and General Motors brace for earnings fireworks
Seeking Alpha News (Fri, 19-Apr 3:00 PM ET)
Merck garners Canadian approval for Keytruda in first-line gastroesophageal cancer
Seeking Alpha News (Fri, 19-Apr 12:03 PM ET)
Cantor Fitzgerald Reaffirms Their Buy Rating on Merck & Company (MRK)
TipRanks (Fri, 19-Apr 12:25 AM ET)
As more rare disease therapies launch, their prices are rising
Seeking Alpha News (Tue, 16-Apr 12:22 PM ET)
Business Wire (Thu, 4-Apr 6:45 AM ET)
Business Wire (Wed, 3-Apr 8:00 AM ET)
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Business Wire (Mon, 1-Apr 6:45 AM ET)
Business Wire (Thu, 28-Mar 6:45 AM ET)
Business Wire (Tue, 26-Mar 6:21 PM ET)
InvestorBrandMedia (Thu, 21-Mar 7:20 PM ET)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Merck Common (New) trades on the NYSE stock market under the symbol MRK.
As of April 19, 2024, MRK stock price climbed to $125.78 with 6,334,793 million shares trading.
MRK has a beta of 0.11, meaning it tends to be less sensitive to market movements. MRK has a correlation of 0.01 to the broad based SPY ETF.
MRK has a market cap of $318.73 billion. This is considered a Mega Cap stock.
Last quarter Merck Common (New) reported $15 billion in Revenue and $.03 earnings per share. This beat revenue expectation by $132 million and exceeded earnings estimates by $.14.
In the last 3 years, MRK stock traded as high as $133.10 and as low as $15.32.
The top ETF exchange traded funds that MRK belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.
MRK stock has underperformed the market in the last year with a return of +12.1%, while SPY returned +21.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MRK shares. However, MRK has outperformed the market in the last 3 month and 2 week periods, returning +6.8% and -1.5%, while SPY returned +4.3% and -3.5%, respectively. This indicates MRK has been having a stronger performance recently.
MRK support price is $123.85 and resistance is $126.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MRK stock will trade within this expected range on the day.